TY - JOUR
AU1 - Kozarek, Richard A.
AB - ORIGINAL ARTICLE A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis Michael Gluck, MD, Nico R. Cantone, BS, John J. Brandabur, MD, David J. Patterson, MD, James E. Bredfeldt, MD, and Richard A. Kozarek, MD ducts. The majority of patients develop cirrhosis of the Goals: The current study presents 1 tertiary endoscopy center’s liver with 10% to 15% harboring or developing 20-year experience using endoscopic therapy to treat patients cholangiocarcinoma, and an estimated 10% of those with symptomatic primary sclerosing cholangitis (PSC). with underlying inflammatory bowel disease (IBD) will develop colon cancer. Patients can suffer recurrent Background: Endoscopic therapy for patients with PSC and episodes of bacterial cholangitis, formation of bile duct dominant strictures has been used for more than 20 years, but stones, and development of abscesses in the liver proximal there is concern that instrumenting a sclerotic biliary tree to strictures. The only definitive cure for PSC is induces risks that outweigh anticipated benefits. orthotopic liver transplantation. Successful clinical Study: In this retrospective chart review, 117 patients with PSC management of PSC hinges on identifying those patients were identified using ICD-9 codes. Patients had a mean age of 47 who have the highest likelihood of 
TI - A Twenty-year Experience With Endoscopic Therapy for Symptomatic Primary Sclerosing Cholangitis
JF - Journal of Clinical Gastroenterology
DO - 10.1097/MCG.0b013e3181646713
DA - 2008-10-01
UR - https://www.deepdyve.com/lp/wolters-kluwer-health/a-twenty-year-experience-with-endoscopic-therapy-for-symptomatic-7p0t0x6uQ2
SP - 1032
EP - 1039
VL - 42
IS - 9
DP - DeepDyve
ER -